Shares of St. Jude Medical (NYSE:STJ) traded 0.14 points or 0.18% higher at $77.49.The total intraday money flow for the shares came in at a disappointing $(-1.81) million. The total upticks amounted to $1.62 million and the total downticks were approximately $3.44 million, with the up/down ratio of 0.47. On a different note, the shares have seen -1% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $0 million in upticks and an outflow of $2.05 million in downticks. The up/down ratio for the block was found to be 0. The net money flow for the block transaction was $(-2.05) million.
Currently the company Insiders own 4.8% of St. Jude Medical shares according to the proxy statements. Institutional Investors own 85.37% of St. Jude Medical shares. On the companys insider trading activities, Fecho Jeff, officer (VP, Global Quality) of St Jude Medical Inc, unloaded 10,408 shares at an average price of $51.71 on February 5, 2016. The total amount of the transaction was worth $538,198, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
St. Jude Medical (NYSE:STJ) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.53 points or 0.69% at $76.82 with 3,985,732 shares getting traded. Post opening the session at $77.3, the shares hit an intraday low of $76.78 and an intraday high of $77.6989 and the price was in this range throughout the day. The company has a market cap of $21,838 million and the number of outstanding shares have been calculated to be 284,277,430 shares. The 52-week high of St. Jude Medical (NYSE:STJ) is $80.84 and the 52-week low is $48.83.
Many analysts have stated their opinion on the company shares. Barclays downgrades its rating on St. Jude Medical (NYSE:STJ). The global brokerage major raises the current price target from $74 per share to $80 per share. Analysts at the Barclays have a current rating of Equal-weight on the shares. The shares were previously rated Overweight. The rating by the firm was issued on May 11, 2016.
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).